A retrospective cohort study assessing the genetic alterations cause intrinsic non-response and/or acquired resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/− binimetinib or alpelisib
Latest Information Update: 26 Nov 2020
At a glance
- Drugs Alpelisib (Primary) ; Binimetinib (Primary) ; Cetuximab (Primary) ; Encorafenib (Primary)
- Indications Colorectal cancer
- Focus Pharmacodynamics; Therapeutic Use
- 26 Nov 2020 New trial record
- 18 Nov 2020 Results published in the British Journal of Cancer